Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EvoPAR-Breast01
jRCT2031240096Recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2024
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of saruparib and camizestrant in breast cancer (4 arms), sponsored by AstraZeneca. Primary endpoint: Progression-Free Survival. Started Jul 2024; status: recruiting.
02
Drugs
saruparibcamizestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2031240096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240096.